PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.15 and traded as high as $0.16. PURE Bioscience shares last traded at $0.16, with a volume of 28,193 shares traded.
PURE Bioscience Stock Up 20.7 %
The firm's 50 day simple moving average is $0.13 and its 200-day simple moving average is $0.15. The company has a market capitalization of $17.81 million, a PE ratio of -4.00 and a beta of 0.21.
Get
PURE Bioscience alerts:
Institutional Inflows and Outflows
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC bought a new stake in PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned 0.92% of PURE Bioscience at the end of the most recent quarter. Institutional investors own 0.92% of the company's stock.
PURE Bioscience Company Profile
(Get Rating)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Featured Articles
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Pure Bioscience，Inc.(場外交易市場代碼：Pure-Get Rating)的股價在週二的交易中突破了200日移動均線。該股的200日移動均線切入位為0.15美元，最高交易價格為0.16美元。Pure Bioscience股票最新報0.16美元，成交量為28,193股。
純生物科學類股上漲20.7%
該公司的50日簡單移動均線切入位為0.13美元，200日簡單移動均線切入位為0.15美元。該公司市值為1,781萬美元，本益比為-4.00，貝塔係數為0.21。
到達
純生物科學警報：
機構資金流入和流出
一家機構投資者最近買入了一隻新的純生物科學股票頭寸。根據IFG Consulting LLC最近提交給美國證券交易委員會(Securities&Exchange Commission)的13F檔案，該公司在第三季度購買了Pure Bioscience，Inc.(OTCMKTS：Pure-Get Rating)的新股份。該機構投資者買入了809,809股該公司股票，價值約161,000美元。截至最近一個季度末，IFG Consulting LLC擁有Pure Bioscience 0.92%的股份。機構投資者持有該公司0.92%的股票。
Pure Bioscience公司簡介
(獲取評級)
Pure Bioscience，Inc.致力於發現、開發和商業化用於病原體和衛生控制的專有抗菌產品。它提供以檸檬酸二氫銀為基礎的消毒和消毒產品。該公司由Michael L.Krall於1992年8月24日創立，總部設在加利福尼亞州的蘭喬庫卡蒙加。
專題文章
- 免費獲取StockNews.com關於純生物科學的研究報告(PURE)
- 在盈利井噴之後，Ciena股票是買入機會嗎？
- 這就是為什麼維京治療公司在肥胖藥物數據上上漲了50%以上
- Meta突破A基點，看起來又成了成長股
- 麥考密克公司的底線已經到了
- 沃爾格林靴子聯盟：藍籌股，高收益扭虧為盈
獲得《純生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pure Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
